{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05092347",
            "orgStudyIdInfo": {
                "id": "R5459-RT-1944"
            },
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen",
            "officialTitle": "A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA \u00d7 CD3 Bispecific Antibodies) for Desensitization of Chronic Kidney Disease Patients in Need of Kidney Transplantation Who Are Highly Sensitized to Human Leukocyte Antigen",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "study-for-desensitization-of-chronic-kidney-disease-in-adult-patients-in-need-of-a-kidney-transplant-who-are-highly-sensitized-to-human-leukocyte-antigen"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-22",
            "studyFirstSubmitQcDate": "2021-10-22",
            "studyFirstPostDateStruct": {
                "date": "2021-10-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of the study is to assess the safety and tolerability of REGN5459 (Part A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and are highly sensitized to human leukocyte antigen (HLA).\n\nThe secondary objectives of the study are to determine/assess the following for REGN5459 (Part A) or REGN5458 (Part B):\n\n* Dose regimen(s) that result in a clinically meaningful reduction of anti-HLA alloantibody levels\n* Effect on calculated panel-reactive antibody (cPRA) levels\n* Time to maximal and clinically meaningful reduction in anti-HLA alloantibody levels\n* Duration of the effect of study drug on the reduction of anti-HLA alloantibodies\n* Effect on circulating immunoglobulin (Ig) classes (isotypes)\n* Pharmacokinetics (PK) properties\n* Immunogenicity"
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Kidney Disease (CKD)"
            ],
            "keywords": [
                "kidney transplant",
                "hemodialysis",
                "desensitization"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "REGN5459",
                    "type": "EXPERIMENTAL",
                    "description": "REGN5459 escalating dose",
                    "interventionNames": [
                        "Drug: REGN5459"
                    ]
                },
                {
                    "label": "REGN5458",
                    "type": "EXPERIMENTAL",
                    "description": "REGN5458 escalating dose",
                    "interventionNames": [
                        "Drug: REGN5458"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "REGN5459",
                    "description": "Administered by intravenous (IV) infusion",
                    "armGroupLabels": [
                        "REGN5459"
                    ],
                    "otherNames": [
                        "BCMAxCD3"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "REGN5458",
                    "description": "Administered by intravenous (IV) infusion",
                    "armGroupLabels": [
                        "REGN5458"
                    ],
                    "otherNames": [
                        "BCMAxCD3",
                        "linvoseltamab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period",
                    "timeFrame": "Up to approximately 4 weeks"
                },
                {
                    "measure": "Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the study",
                    "description": "TEAEs include adverse events of special interest (AESI) and serious adverse events (SAEs)",
                    "timeFrame": "Up to 30 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of Participants with a clinically meaningful reduction in anti-HLA alloantibodies",
                    "description": "Clinically meaningful reduction in anti-HLA alloantibodies are defined as either:\n\n* Reduction in Calculated panel-reactive antibody (cPRA) from baseline, or\n* Reduction in the peak (immunodominant) anti-HLA mean fluorescence intensity (MFI) to \\<5,000, or by \u226550% by Single antigen bead (SAB) assay",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Maximum reduction in the peak (immunodominant) MFI of anti-HLA alloantibodies from baseline",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Percent change from baseline in the peak (immunodominant) MFI",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Percent change from baseline in the sum of MFI of anti-HLA alloantibodies using the SAB assay",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Time to first clinically meaningful reduction in anti-HLA alloantibody levels by SAB assay",
                    "description": "Defined as peak anti-HLA alloantibody MFI \\<5,000 or \u226550% reduction",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Time to maximal reduction in anti-HLA alloantibody levels by SAB assay",
                    "description": "Defined as peak anti-HLA alloantibody MFI \\<5,000 or \u226550% reduction",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Maximum reduction in cPRA from baseline",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Time to first clinically meaningful reduction in cPRA",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Time to maximal reduction in cPRA from baseline",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Duration of a reduction in peak anti-HLA alloantibody to MFI <5,000 or by \u226550% by SAB assay",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Duration of maximal reduction in anti-HLA alloantibody MFI by SAB assay",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Duration of maximal reduction in cPRA by SAB assay",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Serum concentration of Immunoglobulin(Ig) classes over time",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Percent change from baseline of serum concentration of Ig classes",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Concentration of REGN5458 in serum over time",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Concentration of REGN5459 in serum over time",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Incidence of treatment-emergent REGN5458 anti-drug antibodies (ADA) over time",
                    "timeFrame": "Up to 30 weeks"
                },
                {
                    "measure": "Incidence of treatment-emergent REGN5459 ADA over time",
                    "timeFrame": "Up to 30 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Has Chronic Kidney Disease (CKD) requiring hemodialysis, and awaiting kidney transplant on the United Network for Organ Sharing (UNOS), with a cPRA \u226599.9%, or those with a cPRA \\>98% (98.1% to 99.8%) who have spent 5 years or longer on the waitlist\n2. Adequate hematologic and adequate hepatic function as defined in the protocol\n3. Willing and able to comply with clinic visits and study-related procedures\n\nKey Exclusion Criteria:\n\n1. Current or active malignancy not in remission for at least 1 year\n2. Central nervous system (CNS) pathology or history of CNS neurodegenerative or movement disorders\n3. Patients who have had their spleen removed, including patients with functional asplenia\n4. Patients who have received a stem cell transplantation within 5 years\n5. Use of investigational agents within 8 weeks or 5 half-lives of study drug administration (whichever is larger)\n6. Hypogammaglobulinemia, defined as total plasma IgG \\<300 mg/dL at screening\n7. Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone (or anti-inflammatory equivalent) within 72 hours of start of study drug administration\n8. Received a calcineurin inhibitor (eg, tacrolimus, cyclosporine) within 30 days of study drug administration\n9. Received cyclophosphamide, rituximab, obinutuzumab, other anti-CD20 or B cell-depleting agents, or proteasome inhibitors or anti-CD38 therapies (eg, isatuximab, daratumumab) within 6 months of study drug administration\n10. Prior treatment with any anti-BCMA antibody (including antibody drug conjugate or bsAb) or BCMA-directed CAR-T cell therapy\n11. Has received a COVID-19 vaccination within 1 week of planned start of study drug, or for which the planned COVID-19 vaccination would not be completed 1 week before start of study drug\n\nNote: Other protocol defined inclusion / exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of California at San Francisco (UCSF) Connie Frank Transplant Center at UCSF",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Yale University School of Medicine Transplant Surgery",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06519",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Northwestern University Comprehensive Transplant Center",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Johns Hopkins Hospital",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "New York University Langone Health - Transplant Institute",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Pennsylvania-Penn Transplant Institute",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.",
            "accessCriteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency \\[EMA\\], Pharmaceuticals and Medical Devices Agency \\[PMDA\\], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000051436",
                    "term": "Renal Insufficiency, Chronic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26717",
                    "name": "Renal Insufficiency, Chronic",
                    "asFound": "Chronic Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}